Norway on Wednesday signed a deal to swap 100,000 doses of its unused shots made by Johnson & Johnson (JNJ.N) with Lithuania in return for an equal number of doses from Pfizer (PFE.N) in a move to speed up inoculations.
Norway, which is not using the J&J shot, known as Janssen, in its national vaccination programme due to concerns about rare blood clotting issues, will lend 100,000 doses to Lithuania, the government said.In return, Lithuania will loan 100,000 doses of the Pfizer vaccine to Norway, with the delivery scheduled for Thursday.
"I am happy about this deal, which will contribute to both Norway and Lithuania being able to speed up vaccinations," prime minister Erna Solberg said in a statement.This marks Norway's second vaccine loan deal after the country struck an agreement in April with Sweden and Iceland to lend them 216,000 doses of the AstraZeneca
México Últimas Noticias, México Titulares
Similar News:También puedes leer noticias similares a ésta que hemos recopilado de otras fuentes de noticias.
Norway Women's Handball Team Fined For Ditching Bikini Bottoms For ShortsNorway's women's beach handball players gave a big middle finger to their sport's uniform double standards over the weekend ... ditching their required bikini bottoms for shorts during a game -- and the stunt resulted in a fine.
Leer más »
Dr. Vin Gupta encourages J&J vaccine recipients to get a Pfizer or Moderna boosterDr. Vin Gupta explains why he’s encouraging patients who received the single-shot J&J Covid vaccine to get a Pfizer or Moderna booster shot.
Leer más »
J&J raises revenue forecast, estimates $2.5 bln in COVID-19 vaccine salesJohnson & Johnson (JNJ.N) raised its 2021 revenue estimates on Wednesday and forecast it would sell $2.5 billion worth of its COVID-19 vaccine this year, as it strives to quell production and safety problems and catch up with rivals Pfizer and Moderna.
Leer más »
Johnson & Johnson COVID-19 vaccine may not perform as well against Delta variant, says studyThe study, which examined blood samples in a laboratory setting and has not yet been peer-reviewed, suggests that anyone who received the J&J vaccine may...
Leer más »
South Africa’s Biovac to manufacture Pfizer-BioNTech vaccines for AfricaThe South African firm will begin producing the Pfizer-BioNTech Covid-19 vaccine in 2022 and all will be marked for distribution for countries under the African Union.
Leer más »
J&J forecasts $2.5B in revenue from Covid vaccine sales during 2021Although Johnson & Johnson raised its 2021 revenue estimates, its vaccine sales outlook pales in comparison with its peers, reflecting the widening gap in the global vaccine race.
Leer más »